Latest news

Explicyte is indeed planning a new in vivo shuttle session by mid-October, to be held on a series of syngeneic tumor-bearing mouse models such as MCA025 sarcoma, 4T1 & EMT6 breast cancer, MC38 & CT26 colon cancer or Renca renal cancer, among others.

Macrophages - one of the most abundant antigen-presenting cells - represent by themselves a wide group of functionally-different subpopulations involved in several immunological functions, including inflammatory responses and tissue homeostasis maintain & repair.

Because of metastatic development of the disease, among other characteristics, and regardless of survival data, breast cancer was shown to be particularly difficult to treat. However, metastases as well as resistance to therapies continue to be a great challenge and the development of new therapeutic strategies is increasingly necessary.

Explicyte was pleased to participate to the AACR Virtual Annual Meeting, last week to get breakthroughs in Immuno-Oncology and to present our posters featuring our capacities / platforms that support drug discovery.

We will be attending the AACR Virtual Annual Meeting, from June 22 to 24, 2020 to present our posters featuring our capacities / platforms that support drug discovery in Immuno-Oncology.

We will be attending the AACR Virtual Annual Meeting, from June 22 to 24, 2020 to present our posters featuring our capacities / platforms that support drug discovery in Immuno-Oncology.

Take advantage of our upcoming in vitro shuttle session scheduled in early July on our validated M2 macrophage suppression assay, to assess novel immunotherapeutics in time and cost-effective manner.

How about an opportunity to assess your compounds in a comprehensive and cost-effective manner?

Explicyte’s expertise and advanced technologies have been harnessed so as to build a cell-based service platform for immuno-oncology (IO) assessment and drug discovery.